Page last updated: 2024-12-07
m 8506
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
M 8506: RN given for oxalate (1:1) salt; RN for parent cpd not available 8/91 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 130319 |
MeSH ID | M0190071 |
Synonyms (10)
Synonym |
---|
trifluoroacetylprimaquine |
93245-29-5 |
m 8506 |
m-8506 |
ethanone, 1-(8-((4-amino-1-methylbutyl)amino)-6-methoxy-5-quinolinyl)-2,2,2-trifluoro-, ethanedioate (1:1) |
oxalic acid--1-{8-[(5-aminopentan-2-yl)amino]-6-methoxyquinolin-5-yl}-2,2,2-trifluoroethan-1-one (1/1) |
DTXSID90918584 |
1-[8-(5-aminopentan-2-ylamino)-6-methoxyquinolin-5-yl]-2,2,2-trifluoroethanone;oxalic acid |
wefnqsnrejzfqj-uhfffaoysa-n |
AKOS040752871 |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" Because M-8506 is less toxic than primaquine in mice and more effective in radical treatment of simian malaria, further studies on trifluoroacetyl primaquine are worthy to be considered." | ( [Tissue schizontocidal action and acute toxicity of trifluoroacetyl primaquine]. Shao, BR; Ye, XY, 1990) | 0.28 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" cynomolgi sporozoites infected rhesus monkeys 4 dosage regimens of the two agents were compared for radical curative effect." | ( Tissue schizontocidal effect of trifluoroacetyl primaquine in Plasmodium yoelii infected mice and Plasmodium cynomolgi infected monkeys. Shao, BR; Ye, XY, 1991) | 0.28 |
" In order to determine their hemolytic toxicity, we dosed rabbits with M8506 and PQ at a dose of 40 mg/kg per day for 4 days, respectively." | ( [Comparative study on hemolytic toxicity of trifluoroacetoprimaquine and primaquine in rabbits]. Ha, S; Shi, X; Yiao, J; Zhan, C, 1994) | 0.29 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |